Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases.
Fukuoka Igaku Zasshi
; 106(12): 316-22, 2015 Dec.
Article
em En
| MEDLINE
| ID: mdl-27159947
ABSTRACT
PURPOSE:
Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published. MATERIALS ANDMETHODS:
We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.RESULTS:
After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.CONCLUSIONS:
Our results indicate that IFX is efficacious and safe for AS in Japanese patients.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Espondilite Anquilosante
/
Antirreumáticos
/
Infliximab
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Fukuoka Igaku Zasshi
Assunto da revista:
MEDICINA
Ano de publicação:
2015
Tipo de documento:
Article